Northland Securities Reaffirms Corporate Rating for ValiRx Plc (VAL)
ValiRx Plc (LON:VAL)‘s stock had its “corporate” rating reaffirmed by investment analysts at Northland Securities in a note issued to investors on Tuesday.
Separately, Beaufort Securities restated a “speculative buy” rating on shares of ValiRx Plc in a research report on Thursday, August 11th.
Shares of ValiRx Plc (LON:VAL) opened at 6.80 on Tuesday. The stock’s market cap is GBX 3.56 million. The company’s 50-day moving average is GBX 7.01 and its 200-day moving average is GBX 7.99. ValiRx Plc has a 12-month low of GBX 5.75 and a 12-month high of GBX 25.24.
ValiRx Plc Company Profile
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.
Receive News & Stock Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related stocks with our FREE daily email newsletter.